Skip to main content
. Author manuscript; available in PMC: 2012 Jul 9.
Published in final edited form as: Cancer Res. 2011 Mar 28;71(10):3658–3668. doi: 10.1158/0008-5472.CAN-10-3647

Figure 3. STAT3 pathway regulates sensitivity of lung cancer cells to MEK inhibitor treatment.

Figure 3

A, Western blotting confirmed that STAT3 was inhibited with STAT3-specific siRNA. B, Western blotting confirmed that overexpression of constitutive STAT3 in Calu6 and H1437 cells. C, Time course experiment was performed to determine the change of STAT3 expression in H460 cells treated with AZD6244. D, Knockdown of STAT3 sensitized H460 and H226 lung cancer cells to AZD6244. Cells were transfected with 50 nM STAT3-specific siRNA or negative control with Lipofectamine 2000. Then, 24 h after transfection, cells were treated with AZD6244 with different doses as indicated for an additional 72 h. Cell viability was determined by SRB assay. E, Forty-eight hours after transfection with constitutive active STAT3, cells were treated with AZD6244 for another 72 hours, and SRB was performed to determine cell viability.